Novo Nordisk says CagriSema outperformed Lilly’s Zepbound in Phase 3
Novo Nordisk said its CagriSema (cagrilintide plus semaglutide) at 1 mg each achieved greater weight loss than Eli Lilly’s Zepbound in a Phase 3 trial, reporting 12.4% weight loss.
Novo Nordisk said a weight-management and type 2 diabetes drug produced greater weight loss than Eli Lilly’s Zepbound in a phase 3 trial. 4% weight loss in p…